Evidence map›Paper›PMID 29957886›Full record

Trial reportJournal of diabetes investigation2019

Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial.

Wen-Huan Feng, Yan Bi, Ping Li, Ting-Ting Yin, Cai-Xia Gao, Shan-Mei Shen, Li-Jun Gao, Dong-Hui Yang, Da-Long Zhu

Open access · goldAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of diabetes investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 11 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 11 syntheses or guidelines pooled it, 125 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Effects of GLP-1 Receptor Agonists on Muscle Mass, Strength, and Quality in MASLD: A Systematic Review.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Wen-Huan FengDepartment of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China.ORCID http://orcid.org/0000-0002-5145-127X
Yan BiDepartment of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China.ORCID http://orcid.org/0000-0003-3914-7854
Ping LiDepartment of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China.
Ting-Ting YinDepartment of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China.
Cai-Xia GaoDepartment of Traditional Chinese Medicine, Yan'an People's Hospital, Yan'an, China.
Shan-Mei ShenDepartment of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China.
Li-Jun GaoDepartment of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China.
Dong-Hui YangDepartment of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China.
Da-Long ZhuDepartment of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China.
Nanjing Drum Tower Hospital · CNYan'an University · CN

Funding

China Diabetes Young Scientific Talent Research Project 2017-N-05Jiangsu Province's Key Discipline of Medicine XK201105Medical and Health Research Projects of Nanjing Health Bureau in Jiangsu Province of China YKK14055Nanjing Outstanding Youth Fund Projects in Jiangsu Province of China JQX13010Nanjing Science and Technology Development projects in Jiangsu province of China 2013ZD005Nanjing University Central University Basic Scientific Research 14380296National Natural Science Foundation of China 81370947National Natural Science Foundation of China 81570736National Natural Science Foundation of China 81570737Project of National Key Clinical DivisionProject of Standardized Diagnosis and Treatment of Key Diseases in Jiangsu province of China 2015604
6 · The paper itself

Abstract

AIMS/

introductionTo compare the effects of gliclazide, liraglutide and metformin on body composition in patients with type 2 diabetes mellitus with non-alcoholic fatty liver disease. MATERIALS AND

methodsA total of 85 patients were randomly allocated to receive gliclazide (n = 27), liraglutide (n = 29) or metformin (n = 29) monotherapy for 24 weeks. Body composition was measured using dual-energy X-ray absorptiometry.

resultsLiraglutide and metformin reduced total, trunk, limb, android and gynoid fat mass; this also led to weight reduction. However, gliclazide treatment produced no significant changes in weight or fat mass, likely because reductions in fat mass were concomitant with increases in lean tissue mass. Blood glucose concentrations and glycated hemoglobin levels improved in all treatment arms; levels of the latter were lower in patients treated with liraglutide and metformin. Serum alanine aminotransferase concentrations decreased in all treatment arms, whereas serum aspartate aminotransferase concentrations were reduced only by liraglutide and metformin. In all patients, weight loss and total, trunk, limb, and android fat mass reductions were positively correlated with decreases in serum alanine aminotransferase and aspartate aminotransferase levels, whereas reductions in waist circumference were positively correlated with lower serum alanine aminotransferase levels.

conclusionsCompared with gliclazide, liraglutide and metformin monotherapies result in greater weight loss, reductions in body fat mass, and better blood glucose control among type 2 diabetes mellitus patients with non-alcoholic fatty liver disease. Reductions in weight, fat mass and waist circumference favorably affect hepatic function.

Indexed as

AdolescentAdultAgedBiomarkersBlood GlucoseBody CompositionDiabetes Mellitus, Type 2FemaleFollow-Up StudiesGliclazideGlycated HemoglobinHumansHypoglycemic AgentsLiraglutideLiver Function TestsMaleBiomarkersBlood GlucoseGliclazideGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsLiraglutideMetforminAntidiabetic agentsBody compositionType 2 diabetes mellitus

Identifiers

PMID29957886
PMCPMC6400178
OpenAlexW2810643620

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.